Cardiovascular Systems, Inc.
https://csi360.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cardiovascular Systems, Inc.
More Antibodies Than Stars: Overhauling Antibody Drug Discovery
Antiverse co-founder and CEO Murat Tunaboylu, one of In Vivo’s 2022 Rising Leaders, on defining success and why software engineers should consider a career transition to life sciences.
Minute Insight: Bioventus Completes CartiHeal Acquisition Following Agili-C Approval
Bioventus exercised a “call option” to acquire CartiHeal for about $315m, plus up to $135m in milestones. The US FDA recently approved CartiHeal’s Agili-C implant to treat knee joint surface lesions.
Tech Transfer Roundup: How Can Translational Research Help With The Next Pandemic?
Seven international translational research bodies recommend five actions to help better prepare for future outbreaks. Plus an overview of recent COVID-19-focused collaborations.
Chinook Is Advancing Kidney Disease Goals With Surrogate Endpoints, Asian JV
Vancouver biotech is building a pipeline of candidates for rare, severe chronic kidney disease. It has an oral drug in Phase III and an antibody candidate in mid-stage development for IGA nephropathy.
Company Information
- Industry
- Medical Devices
-
Medical Devices
- Implantable Devices
- Infusion Therapy Equipment and Supplies
-
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
-
- Replidyne, Inc.
- Shturman Cardiology Systems, Inc.